Corrigendum to "Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia" [Bioorg. Med. Chem. Lett. 19 (2009) 6225] (DOI:10.1016/j.bmcl.2009.08.091);Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6225-6229

  Sato, Takahiro ^a   Ashizawa, Naoki ^b   Matsumoto, Koji ^b   Iwanaga, Takashi ^b   Nakamura, Hiroshi ^c   Inoue, Tsutomu ^a   Nagata, Osamu ^b  

^a Medical R and D Division   (Japan)

^b Medical R and D Division   (Japan)

^c JOSAI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

CYP3A4; Gout; Hyperuricemia; Structure activity relationships; Triazole derivatives; Xanthine oxidoreductase inhibitor; XO

Indexed keywords

3 ( 3 CYANO 4 PYRIDYL) 5 ( 4 PYRIDYL) 1,2,4 TRIAZOLE; 3,5 DIPYRIDYL 1,2,4 TRIAZOLE; ACYLAMIDRAZONE; ALLOPURINOL; CYTOCHROME P450 3A4; FXY 051; HYDRAZIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; URIC ACID; XANTHINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME ACTIVITY; HYPERURICEMIA; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; URIC ACID BLOOD LEVEL;

RATTUS;

EID: 71749101438     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.026     Document Type: Erratum

References (17)

1. Yamamoto T. Nippon Rinsho 66 (2008) 636
2. Krishnan E., Kwoh C.K., Schumacher H.R., and Kuller L. Hypertension 49 (2007) 298
3. Emmerson B.T. N. Eng. J. Med. 334 (1996) 445
4. Ichida K., Amaya Y., Kamatani N., Nishino T., Hosoya T., and Sakai O. J. Clin. Invest. 99 (1997) 2391
5. Hande K.R., Noone R.M., and Stone W.J. Am. J. Med. 76 (1984) 47
6. Bradlow A. Prescribers' J. 37 (1997) 29
7. 50 values for the XOR-inhibitory activity of the test compounds were determined as follows: bovine milk XOR (2 mU/mL) was incubated with 15 μM xanthine in a 50 mM phosphate buffer (pH 7.4) with or without the test compound at 25 °C. UA formation was determined by the increase in absorbance at 292 nm using a spectrophotometer. The initial rate was calculated from 0 to 2.5 min.
8. The serum UA-lowering activity was measured as follows: the test compounds were administered orally to rats, and their blood was drawn from the orbital sinus 2 or 6 h after the administration. The blood was allowed to clot for 1 h at room temperature and centrifuged. The serum UA levels were measured by the phosphotungstic acid method. Data are represented as the means ± SD of at least three rats.
9. Sato T., Ashizawa N., Iwanaga T., Nakamura T., Matsumoto T., Inoue T., and Nagata O. Bioorg. Med. Chem. Lett. 19 (2009) 184
10. The test compounds were orally administered to rats, and their blood samples were collected from jugular veins at predetermined times. All blood samples were centrifuged to obtain plasma. Aliquots of plasma samples were mixed with acetonitrile containing an appropriate internal standard and centrifuged. Aliquots of the supernatant were measured by the LC-MS system.
11. Baldwin J.J., Kasinger P.A., Novello F.C., and Sprague J.M. J. Med. Chem. 18 (1975) 895
12. Duggan D.E., Noll R.M., Baer J.E., Novello F.C., and Baldwin J.J. J. Med. Chem. 18 (1975) 900
13. The effects of the test compounds on the CYP3A4-mediated hydroxylation of testosterone were examined at a concentration of 10 μM using human liver microsome. The amount of 6β-hydroxytestosterone produced in the reaction was determined by HPLC analysis.
14. Miwatashi S., Arikawa Y., Kotani E., Miyamoto M., Naruo K., Kimura H., Tanaka T., Asahi T., and Ohkawa S. J. Med. Chem. 48 (2005) 5966
15. Venkatakrishnan K., von Moltke L.L., and Greenblatt D. J. Clin. Pharmacokinet. 38 (2000) 111
16. Okamoto K., Matsumoto K., Hille R., Eger B.T., Pai E.F., and Nishino T. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7931
17. Nakazawa T., Miyata K., Omura K., Iwanaga T., and Nagata O. Drug Metab. Dispos. 34 (2006) 1880